{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:14:38Z","timestamp":1792491278402,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n Universal administration of hepatitis B (HepB) vaccine at birth is a cornerstone for hepatitis B virus (HBV) elimination efforts in the US. In 2025, the Advisory Committee on Immunization Practices (ACIP) recommended delaying HepB vaccine initiation among infants born to birth parents who tested negative for hepatitis B surface antigen (HBsAg).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the health and economic impact of delaying HepB vaccination among US infants.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A Markov model of HBV infections was acquired among a cohort infants, born in 2025, up to age 18 years. The model incorporated HBsAg prevalence among birthing parents, HBsAg testing during pregnancy or delivery, vertical or perinatal and household or community HBV transmission among children, and sequalae from chronic infection. This study was conducted in the US.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Eight scenarios in which the first HepB dose was delayed at intervals between 2 months and 12 years, applied either only to infants born to birth parents who tested negative for HBsAg or to parents who either tested negative for HBsAg or had unknown HBsAg status. All delayed vaccination scenarios were compared with administering first HepB dose at birth. Scenarios were modeled with perfect and imperfect adherence to recommendations.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes included acute and chronic HBV infections acquired until age 18 years, additional associated lifetime HBV-related morbidity and mortality, and health care costs (2025 US dollars).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The health and economic outcomes of 3\u202f628\u202f934 infants were modeled in this analysis. All delayed vaccination scenarios resulted in more infections, worse health outcomes, and higher costs than administering first HepB dose at birth. Under perfect adherence, delaying HepB vaccination by 2 months for infants of parents negative for HBsAg led to an additional 90 acute infections (range, 16-107), 76 chronic infections (range, 14-97), 29 HBV-related deaths (range, 6-53), with $16.4 million in added costs for infants born during 1 year. Delaying to 12 years resulted in an additional 190 acute infections (range, 61-233), 50 deaths (range, 15-83), and nearly $30 million in added costs. Delaying HepB vaccination among infants of parents with unknown HBsAg status or imperfect adherence to the vaccination schedule amplified all negative outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this economic evaluation quantified the potential impact of changing ACIP recommendations. Even brief delays in HepB vaccine initiation were associated with a substantial increase in HBV infections, adverse health outcomes, and health care costs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapediatrics.2026.1221","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:30:35Z","timestamp":1777303835000},"page":"1136","source":"Crossref","is-referenced-by-count":7,"title":["Economic Impact of Delaying the Infant Hepatitis B Vaccination Schedule"],"prefix":"10.1001","volume":"180","author":[{"given":"Eric W.","family":"Hall","sequence":"first","affiliation":[{"name":"OHSU-PSU School of Public Health, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhu","family":"Gounder","sequence":"additional","affiliation":[{"name":"Acute Communicable Disease Control Program, Los Angeles County Department of Public Health, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noele P.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Public and Ecosystem Health, Cornell University, Ithaca, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"poi260018r1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/hep.31782","article-title":"An updated assessment of chronic hepatitis B prevalence among foreign-born persons living in the US.","volume":"74","author":"Wong","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"poi260018r2","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000118","article-title":"Prevalence and awareness of hepatitis B virus infection in the US: January 2017-March 2020.","volume":"7","author":"Bixler","year":"2023","journal-title":"Hepatol Commun"},{"issue":"11","key":"poi260018r3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.7326\/M17-1106","article-title":"Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention.","volume":"167","author":"Abara","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8256","key":"poi260018r4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(81)90585-7","article-title":"Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan.","volume":"2","author":"Beasley","year":"1981","journal-title":"Lancet"},{"issue":"6","key":"poi260018r5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/ije\/dyi206","article-title":"A mathematical model to estimate global hepatitis B disease burden and vaccination impact.","volume":"34","author":"Goldstein","year":"2005","journal-title":"Int J Epidemiol"},{"issue":"5","key":"poi260018r6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/archinte.1990.00390170087019","article-title":"Hepatitis B\u2013related sequelae: prospective study in 1400 hepatitis B surface antigen\u2013positive Alaska Native carriers.","volume":"150","author":"McMahon","year":"1990","journal-title":"Arch Intern Med"},{"issue":"10","key":"poi260018r7","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.18502\/ijph.v51i10.10977","article-title":"Horizontal modes of transmission of hepatitis B virus (HBV): a systematic review and meta-analysis.","volume":"51","author":"Sabeena","year":"2022","journal-title":"Iran J Public Health"},{"issue":"10","key":"poi260018r8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/00006454-199210000-00012","article-title":"Prevention of hepatitis B virus infection in the US: a pediatric perspective.","volume":"11","author":"West","year":"1992","journal-title":"Pediatr Infect Dis J"},{"issue":"8643","key":"poi260018r9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(89)92876-6","article-title":"Horizontal transmission of hepatitis B virus.","volume":"1","author":"Davis","year":"1989","journal-title":"Lancet"},{"issue":"8219","key":"poi260018r10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0140-6736(81)92877-4","article-title":"Survival of hepatitis B virus after drying and storage for 1 week.","volume":"1","author":"Bond","year":"1981","journal-title":"Lancet"},{"issue":"3","key":"poi260018r11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/hep.24442","article-title":"Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program.","volume":"54","author":"McMahon","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"poi260018r12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/clinids\/20.4.992","article-title":"Risks of chronicity following acute hepatitis B virus infection: a review.","volume":"20","author":"Hyams","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"4","key":"poi260018r13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1542\/peds.2009-1831","article-title":"Gaps in hospital policies and practices to prevent perinatal transmission of hepatitis B virus.","volume":"125","author":"Willis","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"poi260018r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the US: recommendations of the advisory committee on immunization practices.","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"issue":"30","key":"poi260018r15","first-page":"574","article-title":"Update: recommendations to prevent hepatitis B virus transmission\u2014US.","volume":"44","author":"Centers for Disease Control and Prevention (CDC)","year":"1995","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"poi260018r16","first-page":"33","article-title":"Update: recommendations to prevent hepatitis B virus transmission\u2014US.","volume":"48","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"535","key":"poi260018r17","first-page":"1","article-title":"Births in the US, 2024.","volume":"1","author":"Martin","year":"2025","journal-title":"NCHS Data Brief"},{"issue":"3","key":"poi260018r18","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/cid\/ciz841","article-title":"Trends in hepatitis B infection and immunity among women of childbearing age in the US.","volume":"71","author":"Kushner","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"poi260018r19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/0033354919836958","article-title":"Estimating annual births to hepatitis B surface antigen-positive women in the US by using data on maternal country of birth.","volume":"134","author":"Koneru","year":"2019","journal-title":"Public Health Rep"},{"issue":"5","key":"poi260018r20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/0033354916663183","article-title":"Characteristics of pregnant women with hepatitis B virus infection in 5 US public health jurisdictions, 2008-2012.","volume":"131","author":"Walker","year":"2016","journal-title":"Public Health Rep"},{"issue":"5","key":"poi260018r21","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1542\/peds.2014-3213","article-title":"Outcomes of infants born to women infected with hepatitis B.","volume":"135","author":"Schillie","year":"2015","journal-title":"Pediatrics"},{"issue":"4","key":"poi260018r22","first-page":"1","article-title":"Changes in prenatal care utilization: US, 2019-2021.","volume":"72","author":"Martin","year":"2023","journal-title":"Natl Vital Stat Rep"},{"issue":"1","key":"poi260018r23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amepre.2023.01.041","article-title":"Gaps in prenatal hepatitis B screening and management of HBsAg positive pregnant persons in the US, 2015-2020.","volume":"65","author":"Pham","year":"2023","journal-title":"Am J Prev Med"},{"issue":"5 Pt 2","key":"poi260018r24","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1542\/peds.111.S1.1192","article-title":"Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission.","volume":"111","author":"Euler","year":"2003","journal-title":"Pediatrics"},{"issue":"2","key":"poi260018r27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1542\/peds.2013-0718","article-title":"Cost-effectiveness analysis of the national perinatal hepatitis B prevention program.","volume":"133","author":"Barbosa","year":"2014","journal-title":"Pediatrics"},{"issue":"5","key":"poi260018r28","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1017\/S0950268812001513","article-title":"Hepatitis B virus transmission in preadolescent schoolchildren in 4 multiethnic areas of England.","volume":"141","author":"Balogun","year":"2013","journal-title":"Epidemiol Infect"},{"issue":"8359","key":"poi260018r29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0140-6736(83)90624-4","article-title":"Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.","volume":"2","author":"Beasley","year":"1983","journal-title":"Lancet"},{"issue":"21","key":"poi260018r30","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.vaccine.2012.12.012","article-title":"Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review.","volume":"31","author":"Schillie","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"poi260018r33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/cid\/ciab405","article-title":"Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the US.","volume":"74","author":"Toy","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"poi260018r34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.37765\/ajmc.2020.44069","article-title":"The hepatitis B care cascade using administrative claims data, 2016.","volume":"26","author":"Harris","year":"2020","journal-title":"Am J Manag Care"},{"issue":"4","key":"poi260018r36","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/hep.32474","article-title":"Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose.","volume":"76","author":"Bruce","year":"2022","journal-title":"Hepatology"},{"issue":"4","key":"poi260018r37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.","volume":"151","author":"McMahon","year":"1985","journal-title":"J Infect Dis"},{"issue":"4","key":"poi260018r38","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.amepre.2019.05.005","article-title":"Hepatitis B birth dose: first shot at timely early childhood vaccination.","volume":"57","author":"Oster","year":"2019","journal-title":"Am J Prev Med"},{"issue":"2","key":"poi260018r39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.amepre.2019.10.007","article-title":"Hepatitis B birth dose effects on childhood immunization in the US.","volume":"58","author":"Vader","year":"2020","journal-title":"Am J Prev Med"},{"issue":"2","key":"poi260018r40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jinf.2018.09.014","article-title":"Missed hepatitis B birth dose vaccine is a risk factor for incomplete vaccination at 18 and 24 months.","volume":"78","author":"Wilson","year":"2019","journal-title":"J Infect"},{"issue":"2","key":"poi260018r42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/eurpub\/ckad232","article-title":"Understanding the health system barriers and enablers to childhood MMR and HPV vaccination among disadvantaged, minority or underserved populations in middle- and high-income countries: a systematic review.","volume":"34","author":"Essa-Hadad","year":"2024","journal-title":"Eur J Public Health"},{"issue":"4","key":"poi260018r45","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.vaccine.2017.11.079","article-title":"Safety of currently licensed hepatitis B surface antigen vaccines in the US, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.","volume":"36","author":"Haber","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"poi260018r46","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/01.inf.0000130953.08946.d0","article-title":"Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project.","volume":"23","author":"Eriksen","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"44","key":"poi260018r47","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.15585\/mmwr.mm7244a3","article-title":"Vaccination coverage by age 24 months among children born in 2019 and 2020\u2014National Immunization Survey\u2013Child, US, 2020-2022.","volume":"72","author":"Hill","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"poi260018r48","doi-asserted-by":"publisher","first-page":"F206","DOI":"10.1136\/fn.81.3.F206","article-title":"Unexplained fever in neonates may be associated with hepatitis B vaccine.","volume":"81","author":"Linder","year":"1999","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"11","key":"poi260018r49","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1097\/00006454-200111000-00009","article-title":"Safety of neonatal hepatitis B vaccine administration.","volume":"20","author":"Lewis","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"poi260018r25","unstructured":"US Food and Drug Administration. ARCHITECT HBsAg Next Qualitative Reagent IFU. Accessed November 20, 2025. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf21\/P210003C.pdf"},{"key":"poi260018r26","unstructured":"US Food and Drug Administration. Elecsys HBsAg II Accessed November 20, 2025. https:\/\/www.fda.gov\/media\/176636\/download"},{"key":"poi260018r31","unstructured":"Centers for Disease Control and Prevention. Current CDC vaccine price list. Accessed November 20, 2025. https:\/\/www.cdc.gov\/vaccines-for-children\/php\/awardees\/current-cdc-vaccine-price-list.html"},{"key":"poi260018r32","unstructured":"Center for Medicare & Medicaid Services. 25CLABQ4. Accessed November 20, 2025. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs\/files\/25clabq4"},{"key":"poi260018r35","unstructured":"US Bureau of Labor Statistics. Consumer Price Index. Accessed November 20, 2025. https:\/\/www.bls.gov\/cpi\/"},{"key":"poi260018r41","unstructured":"Choudhury? S. Implications for pharmacies navigating shared clinical decision-making in vaccination. Accessed December 18, 2025. https:\/\/www.pharmacytimes.com\/view\/implications-for-pharmacies-navigating-shared-clinical-decision-making-in-vaccination"},{"key":"poi260018r43","unstructured":"Vrangb\u00e6k? K. International health care system profiles: Denmark. Accessed February 18, 2026. https:\/\/www.commonwealthfund.org\/international-health-policy-center\/countries\/denmark"},{"key":"poi260018r44","unstructured":"Su? J. A review of the safety of hepatitis B birth dose vaccination. Accessed December 18, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-09-18-19\/02-su-hep-b-508.pdf"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2848162\/jamapediatrics_hall_2026_oi_260018_1790892886.60845.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:00:59Z","timestamp":1791212459000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2848162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2026.1221","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}